Back

New RDEB intermediate variant with in-frame partial exon skipping in FN-III-like domain of type VII collagen.

Evtushenko, N.; Kubanov, A.; Martynova, A.; Kondratyev, N.; Beilin, A.; Karamova, A.; Monchakovskaya, E.; Azimov, K.; Nefedova, M.; Bozhanova, N.; Zaklyazminskaya, E.; Gurskaya, N.

2022-09-04 dermatology
10.1101/2022.09.02.22278356
Show abstract

Recessive Dystrophic Epidermolysis Bullosa (RDEB) is a debilitating genodermatosis caused by pathogenic mutations in the COL7A1 gene, which induce absence or reduction in the number of anchoring fibrils. The severity of RDEB depends on the mutation type and localization, but many aspects of this dependence remain to be elucidated. Here, we report a novel variant of RDEB Intermediate in two unrelated patients. Their disease manifestation includes early skin and oral mucosa blistering and is associated with localized atrophic scarring. According to the exome and Sanger sequencing results, both investigated Probands are the carriers of complex heterozygosity in the COL7A1 gene with the same deletion in intron 19 of the COL7A1 gene. RT-PCR followed by sequence analysis revealed skipping of the part of exon19, as well as the rescue of the open reading frame (ORF) of COL7A1 in both Probands. We hypothesize that the mutation in the acceptor splice site leads to the activation of the cryptic donor splice site, resulting in the truncated but partially functional protein and the milder phenotype of intermediate RDEB. This rare type of mutation expands our understanding of RDEB etiology and invites further investigation.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
PLOS ONE
based on 1737 papers
Top 45%
11.2%
2
Frontiers in Medicine
based on 99 papers
Top 0.5%
10.3%
3
Frontiers in Immunology
based on 140 papers
Top 0.7%
8.4%
4
Scientific Reports
based on 701 papers
Top 39%
4.7%
5
Journal of Medical Genetics
based on 22 papers
Top 0.2%
4.5%
6
Human Genomics
based on 13 papers
Top 0.1%
4.5%
7
PLOS Neglected Tropical Diseases
based on 166 papers
Top 5%
3.0%
8
JCI Insight
based on 63 papers
Top 2%
2.8%
9
eLife
based on 262 papers
Top 8%
2.8%
50% of probability mass above
10
Allergy
based on 13 papers
Top 0.8%
2.5%
11
Heliyon
based on 57 papers
Top 3%
2.3%
12
Genetics in Medicine
based on 57 papers
Top 3%
1.8%
13
Journal of Clinical Immunology
based on 11 papers
Top 0.3%
1.6%
14
iScience
based on 74 papers
Top 3%
1.6%
15
Arthritis & Rheumatology
based on 21 papers
Top 0.9%
1.6%
16
Journal for ImmunoTherapy of Cancer
based on 14 papers
Top 2%
1.6%
17
npj Genomic Medicine
based on 18 papers
Top 1%
1.6%
18
Clinical Immunology
based on 12 papers
Top 0.7%
1.6%
19
Cureus
based on 64 papers
Top 13%
1.3%
20
Frontiers in Neurology
based on 74 papers
Top 9%
1.3%
21
Rheumatology
based on 21 papers
Top 0.8%
1.3%
22
Nature Communications
based on 483 papers
Top 34%
1.3%
23
Journal of Allergy and Clinical Immunology
based on 15 papers
Top 1%
1.3%
24
PLOS Pathogens
based on 35 papers
Top 1%
1.3%
25
Frontiers in Nutrition
based on 13 papers
Top 2%
0.8%
26
BMC Cancer
based on 21 papers
Top 5%
0.8%
27
Informatics in Medicine Unlocked
based on 11 papers
Top 3%
0.7%
28
Nature Medicine
based on 88 papers
Top 19%
0.7%